Inari Medical — now part of Stryker — announced that it launched its Artix thrombectomy system for arterial thrombectomies.

The company built Artix for the distinct needs of the peripheral arterial system, according to a news release. It marks Inari’s inaugural entry into the arterial space.

The combined aspiration plus mechanical thrombectomy solution delivers procedural control and versatility. Inari designed it to set a new standard in arterial thrombectomy.

According to Inari, existing therapies can lead to ineffective clot retrieval, leading to additional procedures like open surgery or amputation. It can also lead to significant blood loss, adverse events like arterial embolization and vessel trauma and high rates of lytic use.

Key features include a dual mechanical thrombectomy and aspiration toolkit. This removes acute to chronic clots in a single session via a streamlined procedure. Its aspiration-capable, 8 Fr., low-profile, trackable, kink-resistant sheath comes in two lengths to expand treatment options. Atix also has an innovative over-the-wire mechanical element and a covered nitinol mesh funnel.

Artix builds on Inari’s portfolio of nitinol-enabled devices and systems like the FlowTriever for pulmonary embolism (PE), ClotTriever for deep vein thrombosis (DVT) and the LimFlow system for chronic limb-threatening ischemia (which Inari purchased for up to $415 million in 2023).

“There is a real clinical need to address chronic thrombi and decrease the risk of clot migration. Artix will raise the bar of effective arterial thrombectomy,” said Dr. Tom Tu, chief medical officer of Inari Medical. “We are excited to bring Inari’s core competency in thrombectomy to the arterial space with the goal of improving outcomes.”